Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Diffuse Large B Cell Lymphoma Clinical Trial

Official title:
Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Status Recruiting

Clinical Trial Summary

Immunotherapy with chimeric antigen receptor T-cells (CAR-T) has revolutionized the treatment of oncohematological diseases and its applications in solid tumors and non-neoplastic diseases are advancing. Cytopenias after CAR-T therapy are the most frequent complication in the medium and long term after treatment, they are a cause of morbimortality, and there are no effective therapies available. The general objective of the present research project is to analyze, in a series of 40 patients with diffuse large B-cell lymphoma undergoing consecutive commercial CAR-T therapy at the University Hospital of Salamanca, the characteristics of the hematopoietic niche and the systemic and bone marrow inflammatory status in patients with prolonged cytopenias after CAR-T cell therapy with respect to those without cytopenias and with respect to the pre-treatment situation (performing quantitative and functional analysis of the stroma by immunohistochemistry, flow cytometry and genomic studies, in addition to functional hematopoietic assays-clonogenic assays, long-term cultures-), and to evaluate both in vitro (by co-culturing with macrophages activated by CAR-T/tumor cell interaction and assessing cytokines) and in vivo (in an animal model of lymphoma and CRS) the therapeutic potential of therapies aimed at repairing the hematopoietic bone marrow microenvironment, such as the use of allogeneic mesenchymal cells (MSC) from healthy donors and MSC-derived extracellular vesicles (MSC-EV) studying their effects on inflammatory mediators, hematopoiesis and the cytotoxic effect of CAR-T.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06439173
Study type	Observational
Source	Instituto de Investigación Biomédica de Salamanca
Contact	Fermín Sánchez-Guijo Martín, PhD MD
Phone	+34 923 291384
Email	ferminsg@usal.es
Status	Recruiting
Phase
Start date	January 1, 2024
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04670029` - Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line	Phase 3
Active, not recruiting	`NCT04526834` - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma	Phase 1
Active, not recruiting	`NCT04572763` - Copanlisib Plus Venetoclax in R/R DLBCL	Phase 1/Phase 2
Recruiting	`NCT03676504` - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	Phase 1/Phase 2
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Completed	`NCT03287817` - CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma	Phase 1/Phase 2
Enrolling by invitation	`NCT05645744` - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Completed	`NCT04316624` - A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy	Phase 1
Active, not recruiting	`NCT04555811` - FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL	Phase 1
Terminated	`NCT04189952` - Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma	Phase 2
Recruiting	`NCT01949818` - Treatment of Diffuse Large B Cell Lymphoma	Phase 4
Completed	`NCT01459887` - Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma	Phase 3
Completed	`NCT03242902` - To Decrease Fatigue With Light Therapy	Phase 3
Recruiting	`NCT04104776` - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas	Phase 1/Phase 2
Recruiting	`NCT05018520` - The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk	Phase 3
Withdrawn	`NCT04052061` - QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma	Phase 1
Recruiting	`NCT05020392` - Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma	Phase 3
Recruiting	`NCT05006716` - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies	Phase 1/Phase 2
Completed	`NCT03297424` - A Study of PLX2853 in Advanced Malignancies.	Phase 1
Recruiting	`NCT04545762` - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.